Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag is produced by co-expression of IL-7 RA and TSLP R, has a calculated MW of 51.7 kDa (IL-7 RA) and 50.3 kDa (TSLP R). Subunit IL-7 RA is fused with a human IgG1 Fc fragment at the C-terminus and subunit TSLP R is fused with a human IgG1 Fc fragment at the C-terminus. The reducing (R) protein migrates as 60-80 kDa due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) is more than 85% and the molecular weight of this protein is around 125-140 kDa verified by SEC-MALS.
Immobilized Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) at 5 μg/mL (100 μL/well) can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with a linear range of 0.4-3 ng/mL (QC tested).
Serial dilutions of Monoclonal Anti-Human TSLP Antibody, Human IgG2 were added into Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255): Biotinylated Human TSLP, His,Avitag (Cat. No. TSP-H82Eb) binding reactions. The half maximal inhibitory concentration (IC50) is 1.09688 μg/mL (Routinely tested).
Loaded Human IL-7 RA&TSLP R Heterodimer Protein, Fc Tag&Fc Tag (Cat. No. ILR-H5255) on Protein A Biosensor, can bind Human TSLP Protein, His Tag, premium grade (Cat. No. TSP-H52Hb) with an affinity constant of 134 pM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
PF-06342674 | RN-168; PF-6342674; PF-06342674 | Pfizer Inc | Details | ||
MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Details | |
ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
Lusvertikimab | OSE-127; S-95011 | Phase 2 Clinical | Effimune | Sjogren's Syndrome; Colitis, Ulcerative | Details |
Interleukin-7 (Revimmune SAS) | rhIL-7; CYT-107; CYT-99-007 | Phase 2 Clinical | Cytheris | Urinary Bladder Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Melanoma; Catheter-Related Infections; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Hepatitis C; Ureteral Neoplasms; Urologic Neoplasms; Lymphopenia; Neuroblastoma; Sarcoma; Urethral Neoplasms; Prostatic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Mycobacterium Infections, Nontuberculous; Sepsis; Myeloproliferative Disorders; Myelodysplastic Syndromes; Hepatitis B, Chronic; Carcinoma, Renal Cell; Rhabdoid Tumor; Shock, Septic; Kidney Neoplasms; HIV Infections | Details |
Efineptakin alfa | NT-I7; GX-I7; TJ-107 | Phase 2 Clinical | Genexine Inc | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Sarcoma, Kaposi; Carcinoma, Squamous Cell; Leukoencephalopathy, Progressive Multifocal; Gliosarcoma; Astrocytoma; Lymphopenia; Colorectal Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; HIV Infections; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Coronavirus Disease 2019 (COVID-19); Papillomavirus Infections; Glioblastoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Esophageal Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
This web search service is supported by Google Inc.